Opendata, web and dolomites

LIFEOMEGA

Innovative highly concentrated Omega 3 food supplement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIFEOMEGA project word cloud

Explore the words cloud of the LIFEOMEGA project. It provides you a very rough idea of what is the project "LIFEOMEGA" about.

soup    grams    supports    saturated    unfortunately    life    france    necks    helps    food    11    clinical    uk    receiving    italy    feasibility    juice    emulsion    asthma    arthritis    diseases    constitute    athletes    germany    sachet    joints    innovative    economical    concentration    liquids    acid    retinal    fewer    spain    nutritional    won    minimizing    ip    emulsions    innovation    regulatory    risk    protecting    normally    ideal    commercialization    multiple    permit    cosmetic    pro    people    permits    utilized    cover    cardiovascular    gr    form    ml    lifeomega    market    chemotherapy    chronic    solution    million    requirement    tgs    mentioned    dilution    maximum    sclerosis    concentrated    fatty    musculature    cancer    meeting    quality    liquid    cachexia    dietary    patients    inflammatory    dosages    constituted    epa    maintaining    consists    psoriasis    extra    fats    treatment    business    nutrition    supplement    anorexia    consisting    15    pharma    plan    reduce    milk    bottle    omega    acids    search    usa    weight    competition    suffer   

Project "LIFEOMEGA" data sheet

The following table provides information about the project.

Coordinator
SOLUTEX GC SL 

Organization address
address: CTR DE BARAJAS 24 3-4 PARQUE EMPRESARIAL OMEGA EDIFICIO GAMMA
city: ALCOBENDAS MADRID
postcode: 28108
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.solutex.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.3.2. (SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLUTEX GC SL ES (ALCOBENDAS MADRID) coordinator 50˙000.00

Map

 Project objective

The project aims to develop an innovative food supplement consisting on a high concentrated emulsion of Omega-3 fatty acid EPA. Omega-3 is utilized as a treatment in psoriasis, arthritis, asthma, multiple sclerosis, chronic inflammatory, cancer, high TGs, retinal diseases and cardiovascular failure.

It consists of 15 ml liquid concentration of EPA, minimizing the level of saturated fats. It’s high concentrated -3 grams EPA/ sachet–, so it allows meeting the nutritional requirements in fewer dosages. Similar products in the market are constituted of maximum 1 gr. EPA, in which a higher concentration means higher level of saturated fats. Liquid form permits the dilution in other liquids, as milk, soup, or juice.

These features permit the following applications: 1) Clinical nutrition: most of cancer patients suffer cachexia or anorexia. EPA supports weight management, reduce the pro-inflammatory response and improve quality of life.

2) Dietary supplement: EPA helps maintaining the musculature and protecting the joints, so it is ideal for competition athletes.

Innovation is present in all aspects: application, as the multiple emulsions technology is applied to food products – normally it is applied in cosmetic or pharma-; product, as there are no products in the market offering such a high EPA concentration in liquid form minimizing the saturated fats; design, as it has liquid form; and solution, as the mentioned features constitute a solution for people having an extra requirement of fatty acids.

Goal in phase I is to develop a feasibility study, including a business plan which will cover all aspects of commercialization of LIFEOMEGA: technical, economical, risk assessment, IP, regulatory, bottle necks, market study, partner search, among others.

LIFEOMEGA has a great potential, as it is estimated that cancer patients receiving chemotherapy unfortunately won’t be less than 1 million/year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFEOMEGA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFEOMEGA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.3.2.)

MycoQuest (2015)

Rapid on-site detection of Mycotoxin in wheat

Read More  

PlotLab (2015)

PlotLab - Plot combines with integrated lab equipment for lean breading

Read More  

CHAMPIPACK (2016)

Active packaging for extending lifespan of champignon

Read More